NotesFAQContact Us
Collection
Advanced
Search Tips
Publication Date
In 20250
Since 20240
Since 2021 (last 5 years)0
Since 2016 (last 10 years)0
Since 2006 (last 20 years)2
Descriptor
Drug Therapy2
Mental Retardation2
Quality of Life2
Self Destructive Behavior2
Adults1
At Risk Persons1
Behavior Change1
Behavior Problems1
Check Lists1
Counseling1
Depression (Psychology)1
Family Life1
Foreign Countries1
Hospitals1
Injuries1
Intervention1
Outcomes of Treatment1
Questionnaires1
Severity (of Disability)1
Symptoms (Individual…1
Violence1
More ▼
Source
Journal of Applied Research…2
Author
Murphy, Glynis1
Oliver, Chris1
Read, Stephen G.1
Rendall, Maureen1
Taylor, Lorne1
Publication Type
Journal Articles2
Reports - Research2
Education Level
Audience
Location
United Kingdom (England)1
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Showing all 2 results Save | Export
The Chronicity of Self-Injurious Behaviour: A Long-Term Follow-Up of a Total Population Study
Peer reviewed Peer reviewed
Direct linkDirect link
Taylor, Lorne; Oliver, Chris; Murphy, Glynis – Journal of Applied Research in Intellectual Disabilities, 2011
Background: Self-injurious behaviour (SIB) is a relatively common problem for people with intellectual disabilities and it is known to be associated with various risk markers, such as degree of disability, sensory impairments, and autism (McClintock "et al." 2003). Less is known about its long-term course however. Method: The present…
Descriptors: Intervention, Mental Retardation, Hospitals, Quality of Life
An Open-Label Study of Risperidone in the Improvement of Quality of Life and Treatment of Symptoms of Violent and Self-Injurious Behaviour in Adults with Intellectual Disability
Peer reviewed Peer reviewed
Direct linkDirect link
Read, Stephen G.; Rendall, Maureen – Journal of Applied Research in Intellectual Disabilities, 2007
Background: We examined the benefits of risperidone, including quality of life (QoL), in the treatment of violent and self-injurious behaviour in adults with moderate, severe or profound intellectual disability. Methods: Twenty-four participants received open-label, oral, flexible-dose risperidone of 0.5-6 mg/day for 12 weeks. Efficacy was…
Descriptors: Mental Retardation, Family Life, Quality of Life, Questionnaires